loading
Schlusskurs vom Vortag:
$6.08
Offen:
$6.12
24-Stunden-Volumen:
492.00K
Relative Volume:
0.74
Marktkapitalisierung:
$387.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-36.95M
KGV:
-6.6507
EPS:
-0.92
Netto-Cashflow:
$-33.46M
1W Leistung:
-19.62%
1M Leistung:
-19.20%
6M Leistung:
-22.88%
1J Leistung:
+97.55%
1-Tages-Spanne:
Value
$5.68
$6.29
1-Wochen-Bereich:
Value
$5.68
$7.615
52-Wochen-Spanne:
Value
$3.09
$13.68

Larimar Therapeutics Inc Stock (LRMR) Company Profile

Name
Firmenname
Larimar Therapeutics Inc
Name
Telefon
844-511-9056
Name
Adresse
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Name
Mitarbeiter
42
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
LRMR's Discussions on Twitter

Vergleichen Sie LRMR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
LRMR 6.12 387.94M 0 -36.95M -33.46M -0.92
VRTX 449.14 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.83 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 587.39 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 248.01 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.99 24.89B 3.30B -501.07M 1.03B 11.54

Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-10-19 Eingeleitet Guggenheim Buy
2022-02-15 Herabstufung William Blair Outperform → Mkt Perform
2021-02-10 Eingeleitet JMP Securities Mkt Outperform
2021-02-01 Eingeleitet William Blair Outperform

Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten

pulisher
01:00 AM

Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MyChesCo

01:00 AM
pulisher
Nov 20, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Larimar Therapeutics (NASDAQ:LRMR) Given Outperform Rating at William Blair - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics Presents Additional Data from Phase 1 - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Reports Promising Clinical Data for Friedreich's Ataxia Treatment Nomlabofusp | LRMR Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Buy" from Analysts - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

(LRMR) Trading Signals - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 16, 2024

Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey

Nov 16, 2024
pulisher
Nov 15, 2024

Blue Owl Capital Holdings LP Increases Stake in Larimar Therapeu - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey

Nov 14, 2024
pulisher
Nov 14, 2024

Janus Henderson's Strategic Acquisition in Larimar Therapeutics - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Verition Fund Management LLC Reduces Stake in Larimar Therapeuti - GuruFocus.com

Nov 14, 2024
pulisher
Nov 11, 2024

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart

Nov 11, 2024
pulisher
Nov 08, 2024

PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online

Nov 08, 2024
pulisher
Nov 06, 2024

Goldman Sachs Group Inc's Strategic Acquisition in Larimar Thera - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

When (LRMR) Moves Investors should Listen - Stock Traders Daily

Nov 06, 2024
pulisher
Nov 04, 2024

What is HC Wainwright's Estimate for LRMR FY2024 Earnings? - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

HC Wainwright Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR) - Defense World

Nov 02, 2024
pulisher
Nov 02, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Larimar Therapeutics Inc Reports Q3 2024 Net Loss of $15.5 Milli - GuruFocus.com

Nov 01, 2024
pulisher
Oct 31, 2024

Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Larimar Therapeutics' (LRMR) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Larimar Therapeutics Q3 2024 Financial Update - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Larimar: Q3 Earnings Snapshot - CTPost

Oct 30, 2024
pulisher
Oct 30, 2024

Larimar Therapeutics (NASDAQ:LRMR) Shares Gap UpHere's Why - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 30, 2024
pulisher
Oct 30, 2024

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire

Oct 30, 2024
pulisher
Oct 26, 2024

(LRMR) Investment Analysis and Advice - Stock Traders Daily

Oct 26, 2024
pulisher
Oct 24, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Larimar Therapeutics (NASDAQ:LRMR) Trading Up 6.8%Here's Why - MarketBeat

Oct 24, 2024
pulisher
Oct 20, 2024

Larimar Therapeutics (NASDAQ:LRMR) Now Covered by Analysts at Oppenheimer - Defense World

Oct 20, 2024
pulisher
Oct 17, 2024

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth - Yahoo Finance

Oct 17, 2024
pulisher
Oct 16, 2024

Larimar initiated with bullish view at Oppenheimer on lead drug - MSN

Oct 16, 2024
pulisher
Oct 16, 2024

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga

Oct 16, 2024
pulisher
Oct 16, 2024

Larimar stock gets bullish view at Oppenheimer (LRMR:NASDAQ) - Seeking Alpha

Oct 16, 2024
pulisher
Oct 16, 2024

Oppenheimer Begins Coverage on Larimar Therapeutics (NASDAQ:LRMR) - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

(LRMR) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 10, 2024

Millennium Management LLC Boosts Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Larimar Therapeutics Inc (LRMR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

An Analysis of Larimar Therapeutics Inc (LRMR)’s Potential Price Growth - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Larimar Therapeutics Inc (LRMR) Stock: A Year of Highs and Lows - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Hopeful Week For Insiders Who Bought US$540.7k Of Larimar Therapeutics Stock - Simply Wall St

Oct 09, 2024
pulisher
Oct 07, 2024

Technical analysis of Larimar Therapeutics Inc (LRMR) stock chart patterns - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Financial Metrics Unveiled: Larimar Therapeutics Inc (LRMR)’s Key Ratios in the Spotlight - The Dwinnex

Oct 07, 2024
pulisher
Oct 07, 2024

Analysts Offer Predictions for Larimar Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:LRMR) - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential - Seeking Alpha

Oct 06, 2024
pulisher
Oct 04, 2024

How To Trade (LRMR) - Stock Traders Daily

Oct 04, 2024
pulisher
Oct 04, 2024

Larimar Therapeutics Inc [LRMR] Shares Rise 3.66 % on Thursday - Knox Daily

Oct 04, 2024
pulisher
Oct 04, 2024

Quarry LP Raises Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Oct 04, 2024

Finanzdaten der Larimar Therapeutics Inc-Aktie (LRMR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Larimar Therapeutics Inc-Aktie (LRMR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Flynn James E
Director
Feb 16 '24
Buy
8.74
4,290,617
37,499,993
6,151,406
THOMAS FRANK E
Director
Feb 14 '24
Buy
11.00
2,000
22,000
2,000
Shankar Gopi
Chief Development Officer
Dec 07 '23
Buy
3.73
5,000
18,662
5,000
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):